The National Institute for Health and Care Excellence (NICE) has recommended the CardioMEMS HF System (Abbott) for routine use in England for adults with chronic heart failure at risk for hospital admission. 

The wireless sensor, roughly the size of a paperclip, is permanently implanted in the distal pulmonary artery. It enables home monitoring of pulmonary artery pressure, allowing clinicians to detect early signs of deterioration and intervene before symptoms escalate into emergencies.

Disease Burden and Economic Impact

Heart failure occurs when the heart cannot pump blood efficiently around the body. Common symptoms including breathlessness, fatigue, and swelling.

The condition affects around 920,000 people in the UK and accounts for approximately 1 million hospital bed days each year, representing about 2% of all NHS inpatient stays in England.

Heart failure costs the NHS an estimated £2 billion annually, with a substantial proportion of spending linked to repeated hospital admissions.

How the Device Works

The system features a small pressure sensor implanted in the distal pulmonary artery via minimally invasive right heart catheterisation.

At home, patients lie on a specialised pillow containing an antenna and press a button to transmit daily pressure measurements wirelessly to a secure database. 

Healthcare teams can review pressure trends remotely and adjust medication early, often before patients experience symptoms, helping to prevent decompensation and hospitalisation.

“This technology offers a real opportunity to improve care for people living with chronic heart failure,” said Dr Anastasia Chalkidou, NICE’s HealthTech programme director. “By enabling early detection and timely medication adjustments, it has the potential to reduce emergency admissions and help people manage their condition more effectively from home.”

Patient Selection and Healthcare Impact

The technology is indicated for adults with New York Heart Association class 3 heart failure who have previously been hospitalised and remain at risk of further admission. Patients, or their carers, must be able and willing to take regular measurements and adjust medication as directed.

NICE said the technology could help reduce health inequalities, particularly for people in rural or coastal areas who face long journeys for specialist care. Remote monitoring may also improve access to specialist heart failure services for patients with heart failure with preserved ejection fraction.

However, patients with cognitive impairment, problems with manual dexterity, learning disabilities, or limited digital skills may need additional support from healthcare professionals, carers, or digital enablers to use the system effectively.

Clinical Evidence and Safety Profile

The recommendation is supported by a meta-analysis of three randomised controlled trials — CHAMPION, GUIDE-HF, and MONITOR-HF— including 1898 patients.

Across the studies, use of CardioMEMS was associated with a 34% reduction in heart failure hospital admissions compared with standard care, with a hazard ratio of 0.70 (95% CI, 0.58-0.86).

The device showed an acceptable safety profile. Implantation failure occurred in 1.7% of patients, and device-related complications were rare, at 0.7%. 

Value-Based Care and Cost-Effectiveness

NICE concluded that the CardioMEMS system represents a cost-effective use of NHS resources.

Although the device costs around £9500, economic modelling showed that when NICE’s preferred monitoring schedule is followed, the incremental cost-effectiveness ratio is £14,037 per quality-adjusted life-year gained, well below NICE’s usual funding threshold.

The guidance aligns with the government's 10 Year Health Plan commitment to harness transformative technologies to shift care closer to home and reduce pressure on hospitals.